PURPOSE: Microwave ablation (MWA) is a new minimally invasive method for thermal ablation of benign thyroid nodules with promising results. The aim of this study was to investigate whether MWA has an impact on thyroid function. MATERIALS AND METHODS: Thirty patients with a total of 34 benign thyroid nodules underwent MWA between January 2013 and July 2014. Serum levels of triiodothyronine (T3), thyroxine (T4), thyrotropin (TSH), thyroglobuline (Tg) and additionally antibodies against Tg (anti-Tg), thyrotropin receptors (TRAb) and thyroid peroxidase (anti-TPO) were measured at enrolment, 24 h after MWA, as well as at the 3-month and 6-month follow-up. Moreover, the nodule volume was evaluated to determine effectiveness. RESULTS: Serum TSH, T4, T3 and Tg levels did not change significantly at the 3-month or 6-month follow-up (p > 0.05); thyroid function was not affected by MWA. Antibody levels did not change significantly either; however, two patients developed antibodies after treatment. A volume reduction of 51.4% or 7.85 mL could be demonstrated after 3 months and a reduction of 55.8% or 14.0 mL after 6 months. Slight complications such as mild pain during the ablation or superficial haematomas emerged. The development of Graves' disease and mild Horner's syndrome were observed as more severe side effects. CONCLUSIONS: The data suggest MWA as an alternative for the treatment of benign thyroid nodules. While first results for preservation of thyroid function are positive, further measurements of laboratory data and especially antibodies are necessary.
PURPOSE: Microwave ablation (MWA) is a new minimally invasive method for thermal ablation of benign thyroid nodules with promising results. The aim of this study was to investigate whether MWA has an impact on thyroid function. MATERIALS AND METHODS: Thirty patients with a total of 34 benign thyroid nodules underwent MWA between January 2013 and July 2014. Serum levels of triiodothyronine (T3), thyroxine (T4), thyrotropin (TSH), thyroglobuline (Tg) and additionally antibodies against Tg (anti-Tg), thyrotropin receptors (TRAb) and thyroid peroxidase (anti-TPO) were measured at enrolment, 24 h after MWA, as well as at the 3-month and 6-month follow-up. Moreover, the nodule volume was evaluated to determine effectiveness. RESULTS: Serum TSH, T4, T3 and Tg levels did not change significantly at the 3-month or 6-month follow-up (p > 0.05); thyroid function was not affected by MWA. Antibody levels did not change significantly either; however, two patients developed antibodies after treatment. A volume reduction of 51.4% or 7.85 mL could be demonstrated after 3 months and a reduction of 55.8% or 14.0 mL after 6 months. Slight complications such as mild pain during the ablation or superficial haematomas emerged. The development of Graves' disease and mild Horner's syndrome were observed as more severe side effects. CONCLUSIONS: The data suggest MWA as an alternative for the treatment of benign thyroid nodules. While first results for preservation of thyroid function are positive, further measurements of laboratory data and especially antibodies are necessary.
Authors: Anna Pisani Mainini; Cristian Monaco; Lorenzo Carlo Pescatori; Chiara De Angelis; Francesco Sardanelli; Luca Maria Sconfienza; Giovanni Mauri Journal: J Ultrasound Date: 2016-10-21
Authors: Francesco Morelli; Andrea Sacrini; Giovanni Pompili; Anna Borelli; Silvia Panella; Annamaria Masu; Loredana De Pasquale; Roberta Giacchero; Gianpaolo Carrafiello Journal: Gland Surg Date: 2016-12
Authors: Antonio Barile; Simone Quarchioni; Federico Bruno; Anna Maria Ierardi; Francesco Arrigoni; Aldo Victor Giordano; Sergio Carducci; Marco Varrassi; Giampaolo Carrafiello; Ferdinando Caranci; Alessandra Splendiani; Ernesto Di Cesare; Carlo Masciocchi Journal: Gland Surg Date: 2018-04
Authors: Oscar Maximilian Mader; Nadine Farivar Tanha; Alexander Mader; Christian Happel; Yücel Korkusuz; Frank Grünwald Journal: Eur J Radiol Open Date: 2017-02-05